INTRODUCTION
Many prostate cancer treatments have emerged over the past several years, including 2 radiation therapy options: intensity-modulated radiotherapy (IMRT) and stereotactic body radiation therapy (SBRT). When IMRT entered the market in 2001, it offered conceptual advances over its predecessor, 3-dimensional conformal therapy, in terms of increased precision, but it had yet to accrue long-term data regarding its comparative cancer control, complications, or mortality. [1] [2] [3] Similarly, when SBRT entered the market in 2007, it offered conceptual advances over IMRT in terms of a shorter duration of treatment and had also not yet accrued long-term data regarding its comparative effectiveness. 4, 5 Despite these similarities, early data suggest that these treatments were adopted at different rates. 6, 7 Yet our understanding of the context surrounding the differential adoption of these 2 treatments remains limited. For instance, it is unknown how much the initial trajectories of adoption differed for these 2 treatments. Furthermore, it is unclear whether the factors that influenced the adoption of IMRT also influenced the adoption of SBRT. For example, did the patients who received early IMRT have similar sociodemographics and tumor characteristics as those who received early SBRT? Were the regions that adopted IMRT shortly after its introduction the same as the regions that adopted SBRT? Were the physicians who were considered "early adopters" the same for each treatment? Understanding the clinical and nonclinical factors that influenced the early adoption of these treatments is an important first step in ultimately identifying targets to drive physicians toward a particular technology. To address these knowledge gaps, we conducted a retrospective cohort study to examine the trends in the early adoption of IMRT and SBRT and to investigate factors associated with their early use.
MATERIALS AND METHODS

Data Source and Study Population
We used Surveillance, Epidemiology, and End Results (SEER)-Medicare data to identify men aged 66 years who were diagnosed with prostate cancer between 2001 and 2011. SEER is a nationally representative, population-based registry that comprises approximately 26% of the US population and can be linked to Medicare claims. 8 By using the Medicare Provider Analysis and Review outpatient and carrier files, we further identified men who primarily received radiotherapy (ie, SBRT, IMRT, external-beam radiation, and brachytherapy) within the first 12 months of diagnosis, according to prior methods. 9 We included only fee-for-service beneficiaries who were eligible for both Medicare Parts A and B from 12 months before until 12 months after diagnosis. We excluded men aged 65 years to ensure accurate comorbidity estimation using Medicare claims for the 12-month period before diagnosis. 10 We included men who had prostate cancer as their first and only cancer and excluded those with metastatic disease.
Defining Periods of Early Adoption
Because we were specifically interested in the early adoption patterns of IMRT and SBRT, we limited analyses to the 5 years after each treatment's introduction. The early IMRT adoption period was from 2001 to 2005, and the early SBRT adoption period was from 2007 to 2011. We started the early IMRT adoption period in 2001 and the early SBRT adoption period in 2007 because of the introduction of their respective Healthcare Common Procedure Coding System codes during those years. 11, 12 We investigated starting the adoption periods in 2000 and 2006, but very few patients who received IMRT were identified in 2000; and, similarly, very few who received SBRT were identified in 2006.
Outcome
The outcome variable was the annual adoption probability of the new radiation therapy compared with the existing standard radiation. We defined existing standard radiation based on the predominant treatments at the start of the time period, which included external-beam radiation and brachytherapy from 2001 to 2005 and external-beam radiation, brachytherapy, and IMRT from 2007 to 2011 (Fig. 1) . We included IMRT as a standard radiation treatment during the early SBRT adoption period because it was the most common radiation treatment used for prostate cancer at that time. 6 IMRT precisely delivers high doses of radiation over approximately 40 treatment sessions and is generally considered appropriate for patients with both low-risk and high-risk disease. 2 SBRT also delivers high doses of radiation that are condensed into 5 treatment sessions (ie, hypofractionation) and is considered most suitable for patients with lower risk disease. 4 
Statistical Analyses
Patient/regional factors
We first compared the demographic and clinical characteristics of patients who received new radiation treatments and standard radiation treatments using chi-square tests for each period. We then fit multivariable, hierarchical logistic regression models to examine the factors associated with the receipt of new radiation therapy in both the early IMRT adoption period (period 1) and the early SBRT adoption period (period 2). 13 We used the National Center for Health Statistics' Health Service Areas as a random effect to account for the clustering of patients within markets. 14 We considered using the physician as the clustering variable. However, because of concerns for nonrandom, missing data (potentially because of the transition from Unique Physician Identification Numbers to National Provider Identifiers in 2007), we chose the Health Service Area instead. In addition, physicians are clustered within markets or practices, and there is reason to think that behavior is driven by practice group as much as by individual physician preferences. 15 Patient-level covariates considered to be factors associated with treatment type included age, race/ethnicity, marital status, comorbidity, tumor grade, year after treatment introduction, population, education, median income, and geographic region. Information about population, education, and median income Original Article were obtained from the 2010 US Census. Variables in the final model were selected based on univariable analysis results (P < .10) and/or were based on clinical judgment. Race and ethnicity were self-reported by the patient and were examined because they can influence cancer treatment. 16 Comorbidity was measured using the Klabunde modification of the Charlson index. 12 Tumor grade was used instead of the D'Amico's disease risk classification, because variables like Gleason score were not available in SEER-Medicare before 2004. 17 We also did not incorporate prostate-specific antigen values because of issues with misclassification in SEER. 18 After fitting the model, we calculated the adjusted annual probability of IMRT and SBRT receipt during their respective early adoption years. We then fit another multivariable, hierarchical logistic regression model adjusting for the same covariates as in our main model to examine how IMRT or SBRT use in a Health Service Area the year before treatment influenced the odds of a patient in that Health Service Area receiving IMRT or SBRT in the subsequent year.
Physician factors
Next, we identified the treating physician and evaluated for an association between a physician's treatment pattern during the early IMRT and SBRT adoption periods. To do this, we first identified the treating physician (ie, the radiation oncologist), as previously described. 19 Briefly, we identified the Unique Physician Identification Number and/or the National Provider Identifier in the Medicare claims. We then determined the treating physician by identifying the radiation oncologist who performed the clinical planning and simulation for the treatment. 20 To examine how the pattern of new radiation therapy use among physicians differed across periods 1 and 2, we excluded those who did not treat patients during both time periods. We used a Pearson chi-square test with Yates' continuity correction to test whether or not the proportion of SBRT adopters in period 2 was higher among the physicians who used IMRT compared with standard radiation in period 1. Finally, we examined the distribution of treating physicians among Health Service Areas.
Additional Analyses
We performed 2 sensitivity analyses to assess the robustness of our results. First, because brachytherapy involves seed implantation and may be viewed differently from the other radiation treatments that all involve external beams, we repeated the analyses after removing brachytherapy from the standard treatment group. Second, because IMRT became the predominant radiation therapy within 4 years of its introduction, 6 we performed a sensitivity analysis for a 3-year period of early adoption to examine whether later adopters of IMRT could have biased the results. In both instances, our findings were qualitatively unchanged, so we only present the results from our primary analyses.
We performed all data management and analyses in SAS v9.4 (SAS Institute, Cary, NC) and R v13.2 (R Foundation for Statistical Computing, Vienna, Austria), respectively, using compareGroups for descriptive tables, ggplot2 for graphics, and lme4 for fitting hierarchical logistic models. 21, 22 All tests were 2-sided, and the probability of a type I error was set at .05. The University of Pittsburgh Institutional Review Board exempted this study from full board review.
RESULTS
Patient/Regional Factors
The demographics and clinical characteristics of the study population are summarized in Table 1 Radiation treatments during the early intensitymodulated radiotherapy (IMRT) adoption period (period 1) and the early stereotactic body radiation treatment (SBRT) adoption period (period 2) are illustrated. IMRT is the new treatment in period 1, and SBRT is the new treatment in period 2. The total proportion of treatments during each treatment period was 100%. An asterisk indicates that, during the early SBRT adoption period, IMRT was considered a standard radiation treatment, because it was the most common radiation treatment used for prostate cancer at that time. The results of our multivariable, hierarchical logistic regression models are summarized in Table 2 . In period 1, several patient factors were associated with a higher likelihood of receiving IMRT compared with standard radiation, including older age and poorly/undifferentiated tumors. Several regional factors were associated with a lower likelihood of receiving IMRT compared with standard radiation, including residing in a county with a In period 2, several patient factors were associated with a lower likelihood of receiving SBRT compared with The adjusted annual probability of receiving IMRT was significantly higher than that of receiving SBRT during their respective early adoption years (P < .001) (Fig.  2) . At 5 years, the probability of IMRT use increased from 3% to 44%. Conversely, SBRT use only increased from 1% to 4%. In the early IMRT adoption period, the likelihood of receiving IMRT was significantly higher if IMRT was used in that Health Service Area the previous year (OR, 2.25; 95% CI, 1.92-2.63). The same pattern was observed for SBRT use in the early SBRT adoption period (OR, 2.14; 95% CI, 1.54-2.97).
Physician Factors
The adoption patterns among treating physicians are illustrated in Figure 3 . In total, there were 806 physicians who treated patients with prostate cancer using radiation therapy across both periods 1 and 2. In period 1, 531 physicians were early adopters of IMRT. Among these physicians, 8% (n 5 41) were also early adopters of SBRT in period 2. In period 1, 275 physicians were not early adopters of IMRT (ie, they used standard radiation). Among these physicians, 4% (n 5 11) were early adopters of SBRT in period 2. This difference (8% vs 4%) in the proportion of early SBRT adopters in period 2 approached statistical significance (P 5 .06). The 52 physicians who used SBRT were dispersed across 27 Health Service Areas. The distribution of these physicians and of those who used the other radiation treatments is illustrated in Supporting Figure 1 (see online supporting information).
DISCUSSION
The diffusion of IMRT was brisk, accounting for 44% of radiation treatments within 5 years of introduction, whereas that of SBRT was slow, accounting for 4% of radiation treatments within 5 years. Patients were more likely to receive both IMRT and SBRT compared with the standard radiation therapies at those times if they lived in more populated areas and lived in the northeast as opposed to other regions. IMRT was more likely to be received by older patients and those with poorly differentiated tumors, whereas SBRT was more likely to be received by white patients and those with well differentiated tumors.
One plausible explanation for the observed differences in the patients who received these treatments is the contrasting radiation delivery methods of IMRT and SBRT. A potential advantage of IMRT is the ability to deliver increased doses of radiation with better sparing of normal tissues like the bladder and rectum, thus improving cancer control with decreased toxicity. 1, 2 With the potential to decrease side effects, it is reasonable that providers would prefer to treat older patients with IMRT, thinking it would be a gentler form of radiation. In addition, because higher doses of radiation decrease biochemical recurrence, 23 IMRT may be more appealing for patients with higher grade tumors.
Unlike the patients who received IMRT, those who received SBRT tended to have lower risk disease. Although SBRT delivers higher doses of radiation per session, which proponents believe improves cancer control, 24 there may be some trepidation about using SBRT in higher risk disease because of the limited clinical evidence in this population. 4 Moreover, there are a limited number of opportunities to target the cancer, resulting in a smaller margin for error. Conversely, IMRT is administered with the same number of sessions as its Figure 2 . Adjusted probabilities of receiving intensitymodulated radiotherapy (IMRT) and stereotactic body radiation treatment (SBRT) during their respective early adoption years are illustrated. P values were generated from a model with an interaction term (year after introduction by treatment period). Analyses were adjusted for age, race, marital status, comorbidity, tumor grade, population of county of residence, education in zip code of residence, median income in zip code of residence, and region.
predecessor (3-dimensional conformal therapy); therefore, providers initially were more likely concerned with toxicity than cancer control. 25 Another reason for the decreased use of SBRT among higher risk patients may relate to incentives set up by health policies at the time. During their introduction, both IMRT and SBRT were governed by local coverage determinations, which are decisions by Medicare administrative contractors about coverage for a service based on whether that service is considered reasonable and necessary. 26 Prior work demonstrated that local coverage determinations influenced the adoption of SBRT to some extent. 27 On the basis of the evidence available at the time, they often restricted the use of SBRT to low-risk and intermediate-risk prostate cancers, which would result in decreased receipt among patients with poorly differentiated tumors.
Physicians did not exhibit a propensity for being "early adopters" across the 2 treatment periods. In Rogers' Diffusion of Innovation theory, he describes 5 categories of adopters (ie, innovators, early adopters, early majority, late majority, and laggards). 28 We hypothesized that physicians who were early adopters of IMRT during period 1 would more likely become early adopters of SBRT during period 2. Although this was not the case, the propensity to be an early adopter in both periods approached significance (P 5 .06), and this association may surface in future studies with larger sample sizes.
Despite contrasting reasons for the early adoption of IMRT and SBRT, both of these modalities were used more in the northeast compared with other regions. Regional variation in treatment is well documented, 29, 30 and the northeast has demonstrated an increased propensity for treatments in other conditions. 31 Furthermore, the northeast comprises several markets with high physician and hospital capacity, 32 which generates market competition. For example, the northeast has a higher concentration of institutions with SBRT capabilities than other Figure 3 . Adoption patterns among physicians who used radiation therapy in the early intensity-modulated radiotherapy (IMRT) adoption period (period 1) and the early stereotactic body radiation treatment (SBRT) adoption period (period 2) are illustrated. This parallel set plot represents the 806 physicians who treated patients who had prostate cancer using radiation therapy in both periods. In period 1, 531 physicians were early adopters of IMRT. Among these physicians, 8% (n 5 41) were also early adopters of SBRT in period 2. In the first period, 275 physicians were not early adopters of IMRT (ie, they used standard radiation). Among these physicians, 4% (n 5 11) were early adopters of SBRT in period 2. This difference (8% vs 4%) in the proportion of early SBRT adopters in period 2 approached statistical significance (P 5.06).
parts of the country. 33, 34 This competition can foster the adoption of new technologies to gain an increased market share of patients and attract physicians, among other reasons. 35, 36 Along with geographic region, there are other nonclinical factors that potentially influenced the differential adoption rates of these 2 treatments. Especially early in the SBRT adoption period, health policies and insurance providers often made it difficult to get SBRT approved for prostate cancer. 27 Perhaps more important, there were substantial differences in physician reimbursements. IMRT had favorable reimbursement rates shortly after it was introduced. Consequently, urologists began purchasing IMRT equipment and offering IMRT to their patients. 37 Manufacturers aggressively marketed IMRT to urologists, claiming that treating 1.5 new patients monthly with IMRT could generate more than $425,000 in additional annual revenue per physician. 38 However, total reimbursements for SBRT are lower than those for IMRT. 39 In the current fee-for-service payment model, each treatment session is reimbursed, which discourages the use of a treatment that comprises 5 sessions instead of 40. This discrepancy in reimbursement may also dissuade practices from making the initial investments in equipment and training needed to provide SBRT.
The faster uptake of IMRT likely occurred for both clinical and nonclinical reasons. Clinically, the delivery of IMRT was a more natural extension of its predecessor, 3-dimensional conformal therapy-both of which deliver roughly 40 sessions of radiation over 8 weeks. At the time, it was also well documented that higher doses of radiation led to increased biochemical control, 23 so IMRT was an easy sell for both patients and providers. Conversely, SBRT represented more of a paradigm shift in radiation delivery. It delivered higher doses of radiation in significantly fewer sessions (5 instead of 40), and thus represented a new challenge not only technically but philosophically. For example, there are concerns about toxicity with a treatment that delivers higher doses of radiation in such few sessions. 7, 39, 40 When making decisions, patients and providers may believe that more treatments with lower doses per treatment constitute a safer alternative when deciding between IMRT and SBRT in period 2, whereas no such trade-off was perceived between 3-dimensional conformal therapy and IMRT in period 1, given that they both comprised the same number of treatments.
Our findings should be interpreted in the context of several limitations. First, the results from SEER-Medicare data may not be generalizable to non-SEER regions. For instance, SBRT is prevalent in Florida, where there is a Multi-Institutional Registry for Prostate Cancer Radiosurgery (national clinical trials identifier NCT01226004). 41 Second, few patients in our current study received SBRT. Although we cannot capture all patients who received SBRT using SEER-Medicare data, our data set contains 26% of the US population, and it represents 1 of the largest cancer registries, which provides valuable data on tumor characteristics that are not provided with other national data sets. 8 Third, we compared 2 novel technologies that emerged during different time periods, which could be confounded by several factors present in 1 time period but not the other. For example, more patients underwent active surveillance during the early SBRT adoption period, which could result in a population of radiation patients with more aggressive disease during this period. To help minimize this limitation, we avoided a "head-to-head" comparison of the 2 treatments and, instead, compared each treatment with the standard treatments that were present at that time. Fourth, there are several policy factors (eg, local coverage determinations or certificate-of-need laws) that may influence the adoption of these treatments for which we could not account. Nonetheless, we adjusted for several patient, tumor, and market characteristics and accounted for the nesting of patients within health markets to help minimize confounding from these unmeasured characteristics, among others.
Despite these limitations, this study merits consideration for 3 reasons. First, it provides new evidence demonstrating that many of the factors associated with the early adoption of IMRT and SBRT are different and include both clinical and nonclinical elements. Second, the various rates of adoption among 2 treatments, both of which had limited long-term data at the time of their introduction, emphasize the importance of critically examining the incentives and disincentives related to adoption and of revisiting effectiveness as more long-term data become available. Third, if longer term evidence supports SBRT as a comparable treatment, then transitioning toward SBRT may reduce the treatment burden for patients and lower the costs for our health care system.
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